Shandong Shengzhiyuan Pharmaceutical

Shengzhiyuan in Shandong is a comprehensive R&D company. Its subsidiary, Daguang Pharmaceutical, is a research and B-certification company with a 5,000-square-meter self-owned R&D building and a team of over 100 researchers. It mainly focuses on the development of active pharmaceutical ingredients, pharmaceutical intermediates, drug formulations, consistency evaluation, and innovative drug development. MAH Certificate Platform: Transitioned to MAH in 2020, obtained B certificate in February 2021, and has invested in the development of dozens of self-owned products, which are currently being submitted and approved. There are also products that have won bids in centralized procurement. The B certificate has been in operation and management for nearly 5 years, having undergone multiple inspections and surprise inspections. Pharmaceutical Intermediates Production Platform: Located in a provincial chemical park, with over 20,000 square meters of Class A workshops, currently employing more than 30 staff, specializing in the production of pharmaceutical intermediates, organic intermediates, and fine chemical products. API product development and collaboration: Successfully developed various APIs and pharmaceutical excipients, more than 60 items, such as cyclodextrin series, voriconazole, urapidil hydrochloride, adrenaline series, adefovir dipivoxil, amiodarone hydrochloride, etc.